Evidence map›Paper›PMID 42787207›Full record

ReviewDrug design, development and therapy2026

The Role of Thrombospondin-2 in Myocardial Fibrosis.

Wang Guo, Jie Pu, Hongxin Li, Jiahao Li, Jie Chen, Lingfu Ouyang, Qiang Tang, Hongyu Li

Abstract readReview
In one paragraph

Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wang GuoGraduate School, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, People's Republic of China.
Jie PuGraduate School, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, People's Republic of China.
Hongxin LiGraduate School, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, People's Republic of China.
Jiahao LiGraduate School, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, People's Republic of China.
Jie ChenGraduate School, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, People's Republic of China.
Lingfu OuyangGraduate School, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, People's Republic of China.
Qiang TangThe Second Clinical Medical College, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, People's Republic of China.
Hongyu LiThe Second Clinical Medical College, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myocardial fibrosis is a common pathophysiological process observed in various cardiac diseases and cardiac aging, characterized by excessive accumulation of extracellular matrix proteins in the cardiac interstitium. This process is highly heterogeneous and dynamic, depending on the underlying cardiac pathology and disease stage, and represents a key pathological basis for the development and progression of heart failure. Thrombospondin-2 (TSP-2), a critical extracellular matrix regulatory protein, exhibits complex dual roles in different disease contexts and stages, exerting both cardioprotective and potentially pathological effects. Recent studies have demonstrated that TSP-2 is involved in the pathogenesis of heart failure and may regulate myocardial fibrosis through modulation of extracellular matrix remodeling and related signaling pathways. This review summarizes the regulatory roles of TSP-2 in myocardial fibrosis under various cardiac disease conditions and discusses its potential molecular mechanisms. By integrating current studies, this review provides new insights into the regulatory network of myocardial fibrosis and highlights the potential of TSP-2 as a therapeutic target. However, further mechanistic and translational studies are required to validate the precise role and clinical applicability of TSP-2 in cardiac fibrosis.

Indexed as

Heart DiseasesMyocardiumThrombospondinsAnimalsFibrosisHumansSignal TransductionThrombospondin 2Thrombospondin 2Thrombospondinscardiac agingcardiac diseasesmyocardial fibrosisthrombospondin-2TSP-2

Identifiers

PMID42787207
PMCPMC13600962

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.